Sistema de Salut de Catalunya
Institut Català de la Salut
[Terceño M] Stroke Unit, Department of Neurology Girona Biomedical Research Institute (IDIBGI). Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Interventional Neuroradiology Unit, Department of Neurosciences, Germans Trias i Pujol University Hospital, Badalona, Spain. [Remollo S, Werner M] Interventional Neuroradiology Unit, Department of Neurosciences, Germans Trias i Pujol University Hospital, Badalona, Spain. [Silva Y, Bashir S, Vera-Monge VA, Serena J, Castaño C] Stroke Unit, Department of Neurology Girona Biomedical Research Institute (IDIBGI). Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain
Hospital Universitari de Girona Dr Josep Trueta
2024-03-12T12:18:52Z
2024-03-12T12:18:52Z
2021-02-18
Aneurisme intracranial; Estatines; Aspirina
Aneurismo intracraneal; Estatinas; Aspirina
Intracranial aneurysm; Statins; Aspirin
Background: Acetylsalicylic acid (ASA) and statins have been identified as potentially reducing the risk of intracranial aneurysms (IA) rupture. We aim to determine the effect of this drugs on the risk of rupture of IA. Patients and methods: We performed a retrospective cohort study from a prospective database of patients with IA treated in our institution between January 2013 and December 2018. Demographics, previous oral treatments, presence of multiple aneurysms, size of aneurysm, lobulation, location and morphology of the aneurysms were recorded. Patients were dichotomized as ruptured and unruptured IA. Results: A total of 408 IA were treated, of which 283 (68.6%) were in women. The median age was 53, 194 (47.5%) were ruptured IA. 38 patients (9.3%) were receiving ASA and 84 (20.6%) were receiving statins at the moment of the IA diagnosis. In the multivariable regression analysis, ASA plus statin use and multiple aneurysms were independently associated with unruptured IA (OR 5.01, 95% CI, 1.37-18.33, P = 0.015 and OR 2.72, 95% CI 1.68-4.27, P<0.001, respectively). Whereas, lobulated wall aneurysm and PComA/AComA location were inversely and independently associated with unruptured IA condition (OR 0.34, 95% CI 0.21-0.55, P<0.001 and OR 0.37, 95% CI 0.23-0.60, P<0.001, respectively). However, ASA and statins in monotherapy were not independently associated with unruptured IA condition. Conclusions: In our study population ASA plus statins treatment is independently associated with unruptured IA. Larger and prospective studies are required to explore this potential protective effect against IA rupture.
Article
Published version
English
Aneurismes cerebrals - Prevenció; Estatines (Medicaments cardiovasculars); Aspirina; CHEMICALS AND DRUGS::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenols::Hydroxybenzoates::Salicylates::Aspirin; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Hypolipidemic Agents::Anticholesteremic Agents::Hydroxymethylglutaryl-CoA Reductase Inhibitors; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Intracranial Arterial Diseases::Intracranial Aneurysm; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::enfermedades arteriales intracraneales::aneurisma intracraneal; COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::hidrocarburos::hidrocarburos cíclicos::hidrocarburos aromáticos::derivados del benceno::fenoles::hidroxibenzoatos::salicilatos::aspirina; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::antimetabolitos::hipolipemiantes::anticolesterolemiantes::inhibidores de las hidroximetilglutaril-CoA reductasas
Public Library of Science
PloS One;16(2)
https://doi.org/10.1371/journal.pone.0247153
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
